Moreover, COL11A2 was identified as a subtype-enriched oncogenic driver predominantly expressed in CS1/CS3, and its silencing impaired tumor cell proliferation, invasion, and epithelial–mesenchymal transition (EMT) features. Here, COL11A2 is linked to neoplasm.